BIOCRYST PHARMACEUTICALS, INC. Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $9.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $9.00K.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-03-31 was $56.00K, a 47.37% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2024-03-31 was $38.00K.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $1.06M, a 54.14% increase from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $689.00K, a 86.22% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $370.00K.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|
| 2026-06-30 | $9.00K 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $1.06M 10-K · filed 2026-02-26 | |
| 2025-03-31 | $56.00K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $689.00K 10-K · filed 2026-02-26 | |
| 2024-03-31 | $38.00K 10-Q · filed 2025-11-04 | |
| 2023-12-31 | $370.00K 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |